Patent delisted for Boehringer Ingelheim drug GLYXAMBI

Annual Drug Patent Expirations for GLYXAMBI Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from two suppliers. There are eleven patents…
The post Patent delisted for Boehringer Ingelheim drug GLYXAMBI ap…


Patent delisted for Boehringer Ingelheim drug OFEV

Annual Drug Patent Expirations for OFEV Ofev is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are five patents…
The post Patent delisted for Boehringer Ingelheim drug OFEV appeared first on…


Get email updates

Get new actionable insights and updates from BiotechBlog

Biotechblog